Here are five important observations:
1. Zacks downgraded K2M shares from a “hold” rating to a “sell” rating in a research note issued to investors on Friday, May 29.
2. K2M stock has a one-year low of $12.31 and a one-year high of $26.29.
3. The stock has a 50-day moving average of $23 and a 200-day moving average of $21.
4. The company’s market cap is $1.04 billion.
5. Several other analysts have also recently commented on the stock. It has an average rating of “buy” and a consensus price target of $25.50.
More articles on devices:
Is Smith & Nephew’s cost-conscious strategy working? 5 key notes
NuVasive, VertiFlex, K2M & more — 12 key notes
Shoulder reconstruction device market to see rapid growth — With DePuy Synthes at the helm
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
